Journal article
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
VA Papadimitrakopoulou, TS Mok, JY Han, MJ Ahn, A Delmonte, SS Ramalingam, SW Kim, FA Shepherd, J Laskin, Y He, H Akamatsu, WSME Theelen, WC Su, T John, M Sebastian, H Mann, M Miranda, G Laus, Y Rukazenkov, YL Wu
Annals of Oncology | Published : 2020
Abstract
Background: In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis. Patients and methods: Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum–pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS..
View full abstractGrants
Awarded by Amgen
Funding Acknowledgements
This study (NCT02151981) was funded by AstraZeneca (no grant numbers were applicable in the funding of this study).